High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma.
ibrutinib
idelalisib
infection
lymphoma
venetoclax
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
revised:
11
01
2023
received:
20
11
2022
accepted:
13
01
2023
medline:
5
4
2023
pubmed:
20
1
2023
entrez:
19
1
2023
Statut:
ppublish
Résumé
The infection risk in patients receiving ibrutinib, idelalisib or venetoclax for chronic lymphocytic leukaemia (CLL) or B-cell lymphoma treated outside of clinical trials is incompletely defined. We sought to identify the severe infection rate and associated risk factors in a 'real-world' cohort. We conducted a retrospective cohort study of adult patients with CLL or lymphoma treated with ibrutinib, idelalisib or venetoclax. Of 67 patients identified (ibrutinib n = 53, idelalisib n = 8 and venetoclax n = 6), 32 (48%) experienced severe infection. Severe infection occurred at a rate of 65 infections per 100 person-years, with a median of 17.8 months of therapy. Median time to first infection (IQR) was 5.4 months (1.4-15.9). Poor baseline Eastern Cooperative Oncology Group (ECOG) performance status and high Charlson Comorbidity Index (CCI) score associated with increased risk of severe infection [hazard ratios (95% CI) 1.57 (1.07-2.31, p = .018) and 1.3 (1.05-1.62, p = .016) respectively]. The severe infection rate for patients receiving ibrutinib, idelalisib or venetoclax for lymphoma and CLL exceeded those reported in clinical trials. Patients with poor ECOG or high CCI should be closely monitored for early signs of infection and prevention strategies actively pursued. Further prospective research is required to define optimal antimicrobial prophylaxis recommendations.
Substances chimiques
idelalisib
YG57I8T5M0
ibrutinib
1X70OSD4VX
venetoclax
N54AIC43PW
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
540-547Subventions
Organisme : Monash Health
Organisme : National Health and Medical Research Council
Organisme : Society of Hospital Pharmacists of Australia
Informations de copyright
© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
Références
Intern Med J. 2022 Dec;52(12):2172-2175
pubmed: 36436197
Eur J Haematol. 2018 Apr;100(4):325-334
pubmed: 29285806
Cancer. 1981 Jul 1;48(1):198-206
pubmed: 7237385
Ann Hematol. 2021 Apr;100(4):987-993
pubmed: 33495922
N Engl J Med. 2019 Jun 06;380(23):2225-2236
pubmed: 31166681
Hematol Oncol. 2021 Feb;39(1):141-144
pubmed: 33034902
Lancet Oncol. 2017 Mar;18(3):297-311
pubmed: 28139405
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Blood. 2021 Jan 14;137(2):144-146
pubmed: 33443562
JAMA Oncol. 2020 Feb 1;6(2):248-254
pubmed: 31855259
Clin Infect Dis. 2018 Jan 6;66(1):140-148
pubmed: 29029010
Ther Adv Infect Dis. 2021 Feb 19;8:2049936121989548
pubmed: 33680453
Blood. 2015 Nov 5;126(19):2213-9
pubmed: 26337493
N Engl J Med. 2018 Mar 22;378(12):1107-1120
pubmed: 29562156
Clin Cancer Res. 2018 Sep 15;24(18):4371-4379
pubmed: 29895707
Leuk Lymphoma. 2018 Mar;59(3):625-632
pubmed: 28696801
Blood Adv. 2019 Jun 25;3(12):1799-1807
pubmed: 31196847
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Front Cell Dev Biol. 2021 Mar 11;9:630942
pubmed: 33777941
Eur J Haematol. 2023 May;110(5):540-547
pubmed: 36656100
Blood. 2015 Aug 6;126(6):739-45
pubmed: 26059948
Clin Infect Dis. 2018 Aug 16;67(5):687-692
pubmed: 29509845
Hematol Oncol. 2019 Oct;37(4):496-497
pubmed: 31017684
Am J Hematol. 2019 Dec;94(12):1353-1363
pubmed: 31512258
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Blood Rev. 2018 Sep;32(5):387-399
pubmed: 29571669
Lancet Haematol. 2017 Mar;4(3):e114-e126
pubmed: 28257752
Blood Rev. 2018 Nov;32(6):499-507
pubmed: 29709246
Blood. 2018 May 24;131(21):2357-2366
pubmed: 29483101